D
espite increased awareness, cardiovascular disease remains the leading cause of morbidity and mortality in the United States. 1 Current practice is to identify and treat, when appropriate, patients with coronary artery disease (CAD) with medical and revascularization therapy. Despite this aggressive approach, adverse events rates remain high in patients with CAD. Among patients after acute coronary syndrome enrolled in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE-IT-TIMI 22), in which low-density lipoprotein was Ͻ70 mg/dL, there was a 22% event rate at 2 years after enrollment. 2 In a more stable population of patients requiring percutaneous revascularization, Glaser et al 3 found that Ϸ6% of patients who undergo percutaneous coronary intervention (PCI) will require another procedure in the following year and another 4% will experience a cardiac event without undergoing a procedure. Hence, there is a need for better risk stratification to identify patients at highest risk, so we may concentrate our efforts and resources on improving their disease-free survival.
Clinical Perspective on p 322
One subset of CAD patients at particularly high risk are those with concomitant extracardiac vascular disease. It is well established that patients with coronary disease are more likely to have concomitant vascular disease in other arterial beds. 4 -9 In the Reduction of Atherothrombosis for Continued Health (REACH) registry spanning 44 countries, Ϸ15% of patients worldwide had atherothrombotic disease in Ͼ1 location. 4 A recent analysis from this registry demonstrated that stable outpatients with a history of atherothrombosis have an increased risk of cardiovascular events as a function of the number of involved vascular systems. 9 For example, patients with CAD only, CAD and cerebrovascular disease, and CAD, cerebrovascular disease, and peripheral arterial disease (PAD) showed a 3%, 6.4%, and 7.4% 1-year event rate of cardiovascular death, myocardial infarction (MI), or stroke. 9 This increased risk of cardiovascular events with increasing extent of disease involvement was documented in stable patients with atherosclerosis. Although previous data have demonstrated the association between PAD and outcomes, there is a paucity of data relating the extent of vascular disease and its effect on prognosis in subjects undergoing PCI. The objective of this study is to determine the prevalence and impact of vascular disease severity on in-hospital outcomes in a very large cohort of patients who underwent PCI in New York State.
Methods

Patients
The study population consisted of 69 048 consecutive patients undergoing PCI in New York State between 1998 and 1999. No patients were excluded. Vascular disease burden was assessed by history of aortoiliac, femoral-popliteal, and carotid disease as noted on the case report form for each patient undergoing PCI. No distinction was made whether vascular disease was determined from symptoms, noninvasive testing, or prior surgery. Patients were stratified into 3 groups: CAD alone, CAD and 1 additional site, and CAD and 2 or 3 additional sites.
Data Ascertainment
Prospectively defined data elements including patient demographics, comorbidities, procedural details, complications, and hospital outcomes were required by New York State to be submitted to the Department of Health (DOH) for every angioplasty performed in nonfederal hospitals in the state to make up the Coronary Angioplasty Reporting System Database. The DOH is the coordinating center, and hospitals and their catheterization laboratories were responsible for the accurate documentation and transfer of data. The DOH conducted periodic site visits to check for the accuracy of data entry, and errors and discrepancies were brought to the attention of each laboratory to be rectified.
Statistical Analysis
Categorical variables were compared by 2 analysis. Continuous variables were presented as meanϮSD and were compared using Student t test or ANOVA, as appropriate. Univariable analysis, followed by multivariable logistic regression analysis, was performed to identify independent predictive variables from the categorical and continuous variables. Potential covariates were entered into models if they were clinically relevant or showed univariable differences between groups with a PϽ0.10. To verify our internally derived regression model, we evaluated the independent relationship between extent of vascular disease and mortality in a separate model using variables from a previously published risk score for in-hospital mortality for PCI that was published from the same dataset from a different year. 10 To evaluate the relationship between vascular disease and adverse events in certain high-risk groups, we stratified the data according to sex, chronic kidney disease (defined by a creatinine Ͼ2.5 mg/dL), diabetes, and extent of CAD (1-, 2-, or 3-vessel disease). Statistical significance was defined as PϽ0.05 or CI that did not include 1.0. All probability values are 2 tailed. All analyses were performed using the SPSS 11.0 (SPSS Inc, Chicago, Ill) statistical analysis program.
Results
Among 69 045 patients who underwent PCI, 5915 (8.6%) were previously diagnosed with any vascular disease including aortoiliac (nϭ1941), femoral-popliteal (nϭ2582), and carotid (nϭ2638) disease. Among those with CAD and vascular disease, 4840 (82%) had CAD and vascular disease in 1 additional territory, and 1075 (18%) had CAD and vascular disease in 2 or 3 additional territories.
Baseline characteristics are described in Table 1 . Patients with a greater burden of vascular disease were older, more frequently women, more frequently white, had lower body mass index, and had more atherosclerotic risk factors (diabetes, hypertension, and chronic kidney disease). Previous heart failure, myocardial infarction, coronary artery bypass surgery, and PCI were more common in patients with more extensive vascular disease. Although presentation with MI was more common in patients with CAD alone, cardiogenic shock developed more frequently in those with extensive vascular disease. Mean ejection fraction decreased with increasing vascular disease burden.
Angiographic and procedural characteristics are presented in Table 2 . Overall, the extent of vascular disease was associated with the number of coronary arteries with significant obstructive disease including stenoses of the left main and proximal left anterior descending artery. Glycoprotein IIb/IIIa inhibitors and stents were more commonly used in patients with CAD alone compared with those with increased vascular disease burden. Angiographic success was achieved in 96%, 95%, and 95% in those with CAD alone, CAD and 1 additional site, and CAD and 2 or 3 additional sites, respectively (PϽ0.001).
In-hospital outcomes are displayed in Table 3 . In the overall cohort, in-hospital mortality was 0.8% and increased significantly with the extent of vascular disease (PϽ0.001; Figure) . Compared with patients with CAD alone, in-hospital mortality was higher among patients with CAD and 1 vascular site (odds ratio [OR], 2.89; 95% CI, 2.31 to 3.60; PϽ0.001) and patients with CAD and 2 or 3 vascular sites (OR, 3.78; 95% CI, 2.57 to 5.56; PϽ0.001). There was also a significant relationship between the extent of extracardiac vascular disease and individual adverse events as well as for the combined end point of death, MI, or stroke. This composite end point ranged from 2.7% in patients with CAD alone to 4.9% and 6.1% for patients with 1 or Ն2 disease locations, respectively (PϽ0.001). Similar results were demonstrated after excluding stroke and evaluating death or MI. Mean length of stay was 3.4, 5.2, and 6.2 days in those with CAD alone, CAD and 1 additional site, and CAD and 2 or 3 additional sites, respectively (PϽ0.001).
After adjusting for demographics, clinical characteristics, angiographic findings, and procedural variables, the extent of vascular disease remained an independent predictor of inhospital mortality (Table 4) . Both presence of CAD and 1 additional site (OR, 1.95; 95% CI, 1.52 to 2.50; PϽ0.001) and presence of CAD and 2 or 3 additional sites (OR, 1.91; 95% CI, 1.23 to 2.97; Pϭ0.004) were independent predictors of in-hospital mortality compared with CAD alone. When using vascular disease burden as a continuous variable (CAD alone, CAD ϩ1, CAD ϩ2, and CAD ϩ3 extracardiac vascular beds), each additional vascular bed affected was associated with a 50% increase in in-hospital mortality (OR, 1.50; 95% CI, 1.27 to 1.78; PϽ0.001). Using a previously developed risk model to predict in-hospital mortality among patients undergoing PCI, we evaluated the relationship between the extent of vascular disease and mortality. After adjustment with that externally derived model, the presence of CAD and 1 vascular site (OR, 1.87; 95% CI, 1.46 to 2.39; PϽ0.001) and CAD and 2 or 3 vascular sites (OR, 1.76; 95% CI, 1.13 to 2.74; Pϭ0.013) remained independent predictors of in-hospital mortality compared with CAD alone.
To evaluate the relationship between extent of coronary disease and hospital mortality in various subgroups, we 
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stratified the cohort according to presence of diabetes, chronic kidney disease, sex, and extent of CAD (number of coronary vessels with stenosis Ն50%; data not shown). Increased burden of vascular disease was associated with increased mortality in every subgroup (PϽ0.001 for all).
To assess the impact of specific extracardiac sites of atherosclerosis on outcomes, we explored the risk of in-hospital mortality for predefined cohorts with a single additional arterial bed affected. In-hospital mortality was consistently and markedly higher for patients with isolated aortoiliac (OR, 
Discussion
The principal finding of this study is that the extent of vascular disease among patients with CAD undergoing PCI is independently associated with increased in-hospital mortality. The in-hospital mortality increased from 0.7% in those with CAD without other vascular disease to 2.6% in patients with CAD and vascular disease in 2 or 3 additional sites. The composite of death, MI, or stroke also increased markedly with the extent of vascular disease. A major strength of this study is the inclusion of an unselected and consecutive population of patients with CAD who underwent PCI across an entire state, thus rendering the results applicable to a broad spectrum of patients. PAD is a growing epidemic affecting Ϸ8 million Americans 11 and is associated with significant morbidity and mortality. 5 Patients with symptomatic or asymptomatic PAD have impaired function and quality of life. 12, 13 The risk factors for PAD are similar to those for CAD. 14 It is, therefore, not surprising that vascular disease in one vascular bed is a predictor of concomitant vascular disease in other vascular beds. Presence of PAD is an independent predictor of CAD and its sequelae including MI, stroke, and cardiovascular death. 1,4 -6,8 -10,14,15 Several studies have noted the coexistence of vascular disease in Ͼ1 arterial bed. 4 -9 Recent data from the REACH registry, 9 noted a higher event rate in those with vascular disease in Ͼ1 vascular bed compared with those with disease in only 1 vascular bed. In fact, event rates increased in a stepwise fashion with the number of vascular beds affected. 9 Nevertheless, there is little data whether this increased risk with extent of vascular disease applies to other populations outside the community setting.
Several studies have evaluated the relationship between PAD and adverse events after PCI. 16 -19 Unlike the current community-based study, 2 were single-center studies 17, 19 and 2 analyzed patients from randomized controlled trials. 16, 18 Furthermore, the definition of PAD differed by study; 2 studies 16, 18 had no specific definition but were investigator recorded; 1 study 19 included symptomatic claudication, peripheral revascularization, abdominal aortic disease, or disease of the carotid, cranial, and extracranial arteries; and 1 study 17 used symptomatic PAD (history of intermittent claudication or lower extremity vascular interventions). Despite these differences, all studies found a significant association between concomitant vascular disease and future cardiovascular events. 16 -19 However, only 2 studies noted a significant association between vascular disease and short-term mortality after PCI. 18, 19 No previous study has evaluated the relationship between the burden of vascular disease and adverse outcomes after PCI.
In this study, we noted that 8.6% of patients undergoing PCI were previously diagnosed with concomitant vascular disease. This spectrum of vascular disease included disease in the aortoiliac, femoral-popliteal, and carotid arteries. Consistent with data from the community setting, we demonstrated an increased risk of short-term adverse events as the extent of extracardiac vascular disease increased. For the end point of in-hospital mortality, there was a significant association with extent of vascular disease; events ranged from 0.7% in patients with CAD alone to 2.0% and 2.6% for patients with 1 or Ն2 disease locations, respectively (PϽ0.001). In addition, there was a stepwise increase in the composite of death, MI, or stroke, which ranged from 2.7% in those with CAD alone to 6.1% in those with CAD and 2 or 3 additional sites. Similar results were noted for death or MI. The explanation for the increase in major adverse cardiac events and overall mortality is likely multifactorial and related to the extent of atherosclerotic disease, variation in risk factors, and undertreatment of systemic atherosclerosis.
Limitations
There are several potential limitations of this study. First, the diagnosis of vascular disease was ascertained and recorded by history. Given the universal underdiagnosis of extracardiac vascular disease 6, 20 and the inclusion in this database of only patients with documented aortoiliac, femoral-popliteal, and carotid disease, it is most likely that our study underestimated the true prevalence of vascular disease. Because patients with unrecognized vascular disease were likely included in the control group, this report may actually underestimate the impact of vascular disease on outcomes. Nevertheless, our broad inclusion of all recognized vascular disease among all patients in New York State undergoing PCI represents a community-based PCI population. Second, because of its nonrandomized, retrospective nature, there may remain significant unrecognized differences between groups, even after correction for the observed differences. However, multivariable analysis with 2 separate models was performed and recorded similar results. Furthermore, unlike randomized trials, this study included high-risk patients typically excluded from clinical trials, including those with advanced age and shock, and it is therefore potentially applicable to a broad spectrum of patients. Third, because this study had no long-term follow-up period, it is unknown whether the trends in survival rates found in this study would continue after discharge from the hospital. Fourth, the patients included in this analysis were treated a decade ago. However, there have been no changes in technique, equipment, or adjunctive medications that have altered in-hospital mortality after PCI over this time span. Fifth, we have no information on location of vascular access or access site complications other than those that required surgical repair. Finally, we are unable to determine the cause of the excess mortality in patients with extracardiac vascular disease. This remains an area of active investigation that is being addressed in an ongoing study.
Conclusions
Among patients with CAD undergoing PCI, vascular disease burden is associated with higher rates of adverse events and is an independent predictor of in-hospital mortality. The significant association between extent of vascular disease and morbidity and mortality confirms that atherosclerosis should be addressed as a global arterial disease in patients. These findings underscore the particularly high risk of major clinical events experienced by patients with clinically manifest atherosclerotic disease in multiple vascular beds.
